Nils Ostermann

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 134 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 113 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate

Nils Ostermann, Ilme Schlichting, R. Brundiers et al. · Structure · 2000 · 108 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +11

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS^G12C for the Treatment of Solid Tumors

Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer et al. · Journal of Medicinal Chemistry · 2022 · 95 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by <i>Escherichia coli</i> thymidylate kinase

Arnon Lavie, Nils Ostermann, R. Brundiers et al. · Proceedings of the National Academy of Sciences · 1998 · 90 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +10